SEC Form 4 · accession 0001209191-19-016881
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Director
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $3.72 | Mar 1, 2019 | A | 20,000 | A | — | Mar 1, 2029 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Represents initial grant of options, given to each director upon becoming a member of the board of directors, to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F2The options vest in equal quarterly installments over three years from the date of grant.